Veradermics is trading 5.16% up at $116.67 on October 8, 2026, with no clear company-specific catalyst identified. - Available coverage describes recent clinical-trial milestones and expected data readouts, but does not identify them as the reason for this morning’s rise. - Major U.S. indexes are modestly lower, so the broader market does not explain Veradermics’ gain as a same-direction move.